Kesios Therapeutics, a London, UK-based oncology drug discovery company, raised £1.85m in seed funding.
Imperial Innovations Group plc (AIM: IVO) made the investment and now holds a 48.4% stake in Kesios.
The company is using the funds to advance its pipeline of drug discovery and development programs, validate therapeutic opportunities in cancer for its drug candidates and develop its operational team.
Created to commercialise research led by Professor Guido Franzoso, from the Department of Medicine at Imperial College London, and led by Alain Maiore, CEO, Kesios is developing novel therapeutics for the treatment of multiple myeloma and other blood-related cancers.
FinSMEs
08/10/2014